The AMRIT initiative, operated on a COCO model by HLL Lifecare Limited, has introduced a suite of measures to ensure efficiency, transparency and quality in its pharmacy network.
Key Developments
- Annual statutory audits of financial and operational performance.
- Deployment of an integrated IT system for automatic discount application.
- Direct procurement of branded medicines from reputable manufacturers or authorised distributors to guarantee authenticity.
- Activation of a robust public grievance mechanism via hospital authorities, dedicated email, HLL website and the CPGRAMS portal.
- Implementation of pricing and discount structures as per the MoU between HLL Lifecare and state/host institutions.
Important Facts
The scheme targets patients with high‑cost ailments such as cancer and cardiovascular diseases, aiming to reduce out‑of‑pocket expenditure. Under the COCO model, HLL Lifecare owns the pharmacy premises and manages day‑to‑day operations, ensuring uniformity across states. The annual audits and IT‑driven discounting minimize scope for manual manipulation, while direct sourcing eliminates middle‑men, curbing counterfeit risks.
UPSC Relevance
Understanding AMRIT is crucial for GS1 (Health & Social Justice) as it illustrates government intervention to improve access to essential medicines. The role of MoU showcases inter‑governmental coordination, a recurring theme in Polity. The use of statutory audits and the CPGRAMS portal highlight mechanisms of accountability and citizen‑centred governance, relevant for Ethics and Governance.
Way Forward
To further strengthen the scheme, the Ministry could consider:
- Expanding the IT platform to integrate real‑time stock monitoring across all outlets.
- Periodic third‑party audits in addition to statutory audits for enhanced credibility.
- Scaling the COCO model to include more states, ensuring uniform discount structures nationwide.
- Increasing public awareness of the grievance channels to improve utilization.
These steps would reinforce the scheme’s objective of affordable, authentic medicines while reinforcing transparency and accountability in public health delivery.